首页> 外文OA文献 >A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells
【2h】

A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells

机译:PHRE-EGR1-HSV-TK /抗CD133MCAB-131I / MFH由肝癌干细胞介导的PHRE-EGR1-HSV-TK /抗CD133MCCAB-131I / MFH的组合治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

It has been evidenced that liver cancer stem cells (LCSCs) are to blame hepatocellular carcinoma (HCC) occurrence, development, metastasis, and recurrence. Using iron-platinum nanoparticles (FePt-NPs) as a carrier and CD133 antigen as a target, a new strategy to targetly kill LCSCs by integrating HSV-TK suicide gene, 131I nuclide irradiation, and magnetic fluid hyperthermia (MFH) together was designed and investigated in the present study. The results showed that FePt-NPs modified with PEI (PEI-FePt-NPs) could bind with DNA, and the best binding ratio was 1 : 40 (mass ratio). Moreover, DNA binding to PEI-FePt-NPs could refrain from Dnase1 enzyme digestion and could release under certain conditions. LCSCs (CD133+ Huh-7 cells) were transfected with pHRE-Egr1-HSV-TK by PEI-FePt-NPs, and the transfection efficiency was 53.65±3.40%. These data showed a good potential of PEI-FePt-NPs as a gene transfer carrier.131I was labeled with anti-CD133McAb in order to facilitate therapy targeting. The combined intervention of pHRE-Egr1-HSV-TK/anti-CD133McAb-131I/MFH mediated by PEI-FePt-NPs could greatly inhibit LCSCs’ growth and induce cell apoptosis in vitro, significantly higher than any of the individual interventions (p<0.05). This study offers a practicable idea for LCSC treatment, and PEI-FePt-NPs may act as novel nonviral gene vectors and a magnetic induction medium.
机译:已经证明,肝癌干细胞(LCSCs)应归咎于肝细胞癌(HCC)发生,发育,转移和复发。使用铁 - 铂纳米颗粒(FEPT-NPS)作为载体和CD133作为靶标,设计了通过将HSV-TK自杀基因,131I核辐照和磁性流体热疗(MFH)集成到靶向杀死LCSC的新策略在本研究中调查。结果表明,用PEI(PEI-FEPT-NPS)修饰的备用NPS可与DNA结合,最佳结合比为1:40(质量比)。此外,与PEI-FEPT-NPS结合的DNA可以避免DNase1酶消化,并且可以在某些条件下释放。 LCSCs(CD133 + Huh-7细胞)通过PEI-FePt系的NP与pHRE-EGR1-HSV-TK转染,且转染效率53.65±3.40%。这些数据显示PEI-FEPT-NPS的良好潜力,因为基因转移载体以抗CD133mcab标记,以便于治疗靶向。 PHRE-EGR1-HSV-TK /抗CD133MCAB-131I / MFH的组合干预由PEI-NES-NPS介导的介导的能够极大地抑制LCSCs的生长和诱导体外细胞凋亡,显着高于任何个体干预措施(P < 0.05)。本研究提供了可行的LCSC治疗理念,PEI-FEPT-NPS可以充当新的非血流基因载体和磁感应介质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号